CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

A single subcutaneous dose of Regeneron’s investigational CIDEBsiRNA reduced liver fat by 58–80% at week 36 in a first-in-human trial of 30 treated adults with MASLD; 62% had liver fat normalized, versus none of 10 placebo recipients. Reductions were dose-dependent and liver-injury markers improved through week 36, with adverse-event rates generally similar to placebo; one severe serious hyperglycemia event was not attributed to the drug. These Phase 1/2 results support further evaluation, but efficacy and safety remain investigational, with longer-term safety and histologic outcomes under study in ongoing trials.

Analysis

The investable signal is target validation plus a potentially differentiated dosing profile—not yet proof of clinical benefit. A large, durable MRI-PDFF change could support advancement, but liver-fat reduction is a pharmacodynamic surrogate; the commercial thesis still requires biopsy-based MASH resolution/fibrosis data, larger-sample safety, and ultimately outcomes that matter to patients and payers. With only 30 treated participants, rare or cumulative safety risks remain unresolved.

For REGN, this adds pipeline optionality but is unlikely by itself to reset consolidated earnings expectations: value depends on clinical conversion, pricing/access, and whether twice-yearly dosing wins against alternatives such as Madrigal’s resmetirom or broader metabolic therapies from Novo Nordisk. The lack of nausea/vomiting in this small study is not yet a durable competitive advantage. Alnylam’s economics are secondary to the clinical read-through: it receives milestones and royalties, but the article gives no terms, so do not translate the result into a material ALNY earnings revision without modeling those rights.

Near term, the November 10 investor event is a catalyst for trial design, timelines, and portfolio prioritization, not efficacy confirmation. Over 1–3 months, watch whether the company discloses histology endpoints, enrollment, and dose selection. Over 6–18 months, biopsy results and longer exposure are the key repricing gates. The contrarian risk is extrapolating an impressive imaging result into a high-probability launch: without histologic benefit, the signal may not displace established therapies or earn broad reimbursement.

Key Decisions for Investors

• Do not chase REGN solely on this release; treat CIDEBsiRNA as pipeline optionality until histologic efficacy and longer-term safety are reported. The small early-stage study does not establish commercial or earnings impact.
• Use the November 10 roundtable as a diligence catalyst: verify dose selection, Phase 2/3 design and timing, biopsy endpoints, safety follow-up, and how the program may be used alongside existing MASH treatments.
• Keep ALNY out of a direct read-through trade pending the collaboration’s milestone and royalty economics. Reassess only if disclosed terms or development progress imply a material change to expected collaboration revenue.
• Falsification/watch item: downgrade the thesis if subsequent trials fail to reproduce liver-fat reductions, do not show biopsy-based MASH/fibrosis benefit, reveal dose-limiting or cumulative safety issues, or management delays pivotal milestones.